Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Pharmacology|January 1, 1991
Gastric acid inhibitory profile of saviprazole (HOE 731) compared to omeprazoleA W Herling, T Scholl, M Bickel, et al.
FEBS Letters|September 22, 1998
Soluble IL-1 receptor type I binds to human dermal fibroblasts and induces calcium fluxB Spörri, U N Wiesmann, R M Ochsenbein, et al.
Biochemical and Biophysical Research Communications|April 16, 1985
2-((2-Pyridylmethyl)sulfinyl)benzimidazoles: acid sensitive suicide inhibitors of the proton transport system in the parietal cellG Rackur, M Bickel, H W Fehlhaber, et al.
HIV Medicine|December 10, 2023
Areas with high HIV prevalence: A spatial analysis of nationwide claims data in GermanyM K Akmatov, E Hu, R Rüsenberg, et al.
Deutsche Medizinische Wochenschrift (1946)|September 12, 2013
[Changing spectrum of renal disease in HIV infection]O Jung, H S Haack, H-R Brodt, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|July 1, 1994
Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, LufironilE Baader, M Bickel, D Damm, et al.
HIV Medicine|May 7, 2005
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral loadM Bickel, V Rickerts, C Stephan, et al.
Deutsche Medizinische Wochenschrift (1946)|November 13, 2009
[Novel influenza H1N1/2009: virus transmission among health care worker]S Wicker, H F Rabenau, M Bickel, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patientsM Bickel, A Bodtländer, G K Knecht, et al.
The Journal of Biological Chemistry|September 15, 1992
Liver-specific drug targeting by coupling to bile acidsW Kramer, G Wess, G Schubert, et al.
Pageof 12